FDA
-
-
-
-
-
-
-
Kezar Life Sciences Announces Completion of Enrollment of Its Phase 2 PRESIDIO Clinical Trial of KZR-616 in Polymyositis and Dermatomyositis
-
-
-
-
-
-
-
Kezar Life Sciences Reports First Quarter 2019 Financial Results and Provides Business Update
251,875 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All